IMVT IMMUNOVANT INC revenue, earnings and financials
For the quarter ended June 30, 2026, IMMUNOVANT INC reported revenue of n/a, net income of −$153M and diluted EPS of −$0.75; for the fiscal year ended March 2026 revenue was n/a.
IMVT annual revenue and earnings
- Fiscal year ended Mar 2026: revenue n/a, gross profit n/a, operating income n/a, net income −$506M (margin n/a), EPS −$2.77
- Fiscal year ended Mar 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$414M (margin n/a), EPS −$2.73
- Fiscal year ended Mar 2024: revenue n/a, gross profit n/a, operating income n/a, net income −$259M (margin n/a), EPS −$1.88
- Fiscal year ended Mar 2023: revenue n/a, gross profit n/a, operating income n/a, net income −$211M (margin n/a), EPS −$1.71
- Fiscal year ended Mar 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$157M (margin n/a), EPS −$1.43
IMVT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$153M, EPS −$0.75
- Quarter ended Mar 31, 2026 (from the annual report): revenue n/a, net income −$148M, EPS −$0.72
- Quarter ended Dec 31, 2025: revenue n/a, net income −$111M, EPS −$0.61
- Quarter ended Sep 30, 2025: revenue n/a, net income −$127M, EPS −$0.73
- Quarter ended Jun 30, 2025: revenue n/a, net income −$121M, EPS −$0.71
- Quarter ended Mar 31, 2025 (from the annual report): revenue n/a, net income −$106M, EPS −$0.63
- Quarter ended Dec 31, 2024: revenue n/a, net income −$111M, EPS −$0.76
- Quarter ended Sep 30, 2024: revenue n/a, net income −$109M, EPS −$0.74
- Quarter ended Jun 30, 2024: revenue n/a, net income −$87.2M, EPS −$0.60
- Quarter ended Mar 31, 2024 (from the annual report): revenue n/a, net income −$75.3M, EPS −$0.50
- Quarter ended Dec 31, 2023: revenue n/a, net income −$51.4M, EPS −$0.36
- Quarter ended Sep 30, 2023: revenue n/a, net income −$58.7M, EPS −$0.45
- Quarter ended Jun 30, 2023: revenue n/a, net income −$73.9M, EPS −$0.57
- Quarter ended Mar 31, 2023 (from the annual report): revenue n/a, net income −$59.4M, EPS −$0.46
- Quarter ended Dec 31, 2022: revenue n/a, net income −$63.2M, EPS −$0.49
- Quarter ended Sep 30, 2022: revenue n/a, net income −$47.9M, EPS −$0.41
- Quarter ended Jun 30, 2022: revenue n/a, net income −$40.4M, EPS −$0.35
- Quarter ended Mar 31, 2022 (from the annual report): revenue n/a, net income −$47.2M, EPS −$0.41
- Quarter ended Dec 31, 2021: revenue n/a, net income −$41.4M, EPS −$0.36
- Quarter ended Sep 30, 2021: revenue n/a, net income −$37.7M, EPS −$0.35
IMVT cash flow, buybacks and dividends
- Fiscal year ended Mar 2026: operating cash flow −$407M, share buybacks n/a
- Fiscal year ended Mar 2025: operating cash flow −$376M, share buybacks n/a
- Fiscal year ended Mar 2024: operating cash flow −$214M, share buybacks n/a
- Fiscal year ended Mar 2023: operating cash flow −$188M, share buybacks n/a
- Fiscal year ended Mar 2022: operating cash flow −$106M, share buybacks n/a
IMVT balance sheet
- Jun 30, 2026: cash $798M, total assets $852M, total liabilities $117M, shareholders' equity $735M
- Mar 31, 2026: cash $902M, total assets $957M, total liabilities $104M, shareholders' equity $853M
- Dec 31, 2025: cash $995M, total assets $1.05B, total liabilities $66.3M, shareholders' equity $986M
- Sep 30, 2025: cash $522M, total assets $583M, total liabilities $63.3M, shareholders' equity $520M
- Jun 30, 2025: cash $599M, total assets $661M, total liabilities $52.9M, shareholders' equity $609M
- Mar 31, 2025: cash $714M, total assets $776M, total liabilities $68.8M, shareholders' equity $707M
- Dec 31, 2024: cash $375M, total assets $421M, total liabilities $68.3M, shareholders' equity $353M
- Sep 30, 2024: cash $473M, total assets $516M, total liabilities $66.7M, shareholders' equity $449M
Is IMVT profitable?
No. IMMUNOVANT INC lost $538M over the last four quarters.
What is IMVT's EPS?
Diluted earnings per share over the last four quarters were −$2.81; −$0.75 in the latest quarter.